RECOMMENDATIONS

EULAR recommendations for the management of primary small and medium vessel vasculitis

C Mukhtyar¹, L Guillevin², M C Cid³, B Dasgupta⁴, K de Groot⁵, W Gross⁶, T Hauser⁷, B Hellmich⁸, D Jayne⁹, C G M Kallenberg¹⁰, P A Merkel¹¹, H Raspe⁶, C Salvarani¹², D G I Scott¹³, C Stegeman¹⁰, R Watts¹⁴, K Westman¹⁵, J Witter¹⁶, H Yazici¹⁷, R Luqmani¹, for the European Vasculitis Study Group

¹ University of Oxford, Oxford, UK
² University of Paris Descartes, Paris, France
³ Hospital Clinic, Barcelona, Spain
⁴ Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, UK
⁵ Klinikum Offenbach, Offenbach, Germany
⁶ University Hospital of Schleswig-Holstein, Lübeck, Germany
⁷ University Hospital, Zurich, Switzerland
⁸ Kreiskrankenhaus Plochingen, Plochingen, Germany
⁹ Addenbrooke’s Hospital, Cambridge, UK
¹⁰ University Medical Centre Groningen, Groningen, The Netherlands
¹¹ Boston University School of Medicine, Boston, Massachusetts, USA
¹² Arcispedale S Maria Nuova, Reggio Emilia, Italy
¹³ Norfolk and Norwich University Hospital Trust, Norwich, UK
¹⁴ Ipswich Hospital NHS Trust, Ipswich, UK
¹⁵ Malmo University Hospital, Malmo, Sweden
¹⁶ US Food and Drug Administration, Rockville, Maryland, USA
¹⁷ University of Istanbul, Istanbul, Turkey

R Luqmani, Nuffield Orthopaedic Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK; raashid.luqmani{at}noc.anglox.nhs.uk

Objectives: To develop European League Against Rheumatism (EULAR) recommendations for the management of small and medium vessel vasculitis.

Methods: An expert group (consisting of 10 rheumatologists, 3 nephrologists, 2 immunologists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search using a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of small and medium vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.

Results: In all, 15 recommendations were made for the management of small and medium vessel vasculitis. The strength of recommendations was restricted by low quality of evidence and by EULAR standardised operating procedures.

Conclusions: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Gomez-Puerta, J. A., Bosch, X. (2009). Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis: An Update. Am. J. Pathol. 175: 1790-1798 [Abstract] [Full Text]  
• de Groot, K., Harper, L., Jayne, D. R.W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., Tesar, V., Vanhille, P., Westman, K., Savage, C. O.S., for the EUVAS (European Vasculitis Study Group), (2009). Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody--Associated Vasculitis: A Randomized Trial. ANN INTERN MED 150: 670-680 [Abstract] [Full Text]  
• Jourde, N., Mancini, J., Chiche, L., Gelber, A. C., Pagnoux, C., Guillevin, L., the French Vasculitis Study Group and the Wegener', (2009). Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.. NEJM 360: 1358-1359 [Full Text]